BACKGROUND: Various evidence show that CD97 plays an important role in tumor differentiation, migration, invasiveness, and metastasis by binding its cellular ligand CD55. CD55 is a complement regulatory protein expressed by cells to protect them from bystander attack by complement, and it has been shown to be an indicator of poor prognostic in several cancers. METHODS: CD97 and CD55 stains were detected in tumor tissues from 71 cases of rectal adenocarcinomas and their corresponding normal colorectal tissues by immunohistochemistry. RESULTS: The expressions of CD97 and CD55 in rectal tumor tissues were significantly higher than those in normal colorectal tissues (P < 0.05, both). The patients with recurrence and/or metastasis had significantly higher expressions of CD97 at tumor cells and CD55 at stroma (67.8% [21/31] and 63.6% [21/33]) at the invasion front than those patients without recurrence and/or metastasis (25.0% [10/40] and 26.3% [10/38]). The expression of CD97 at tumor cell at the invasion front showed modest correlation with that of CD55 in the stroma at the invasion front(r = 0.392, P < 0.01). Univariate analysis revealed that lymph node metastasis (P = 0.001), stages II-IV (P = 0.026), and strong CD97 expression at tumor invasion front (P = 0.002) were shown to have a significant adverse impact on the postoperative survival rate. Moreover, lymph node metastasis (P = 0.037) and strong CD97 expression (P = 0.015) were associated with poor survival in a multivariate analysis. CONCLUSIONS: Elevated expression of CD97 and its ligand CD55 at the invasion front correlate with tumor recurrence and metastasis, and CD95 may be a poor prognostic factor for rectal adenocarcinoma.
BACKGROUND: Various evidence show that CD97 plays an important role in tumor differentiation, migration, invasiveness, and metastasis by binding its cellular ligand CD55. CD55 is a complement regulatory protein expressed by cells to protect them from bystander attack by complement, and it has been shown to be an indicator of poor prognostic in several cancers. METHODS:CD97 and CD55 stains were detected in tumor tissues from 71 cases of rectal adenocarcinomas and their corresponding normal colorectal tissues by immunohistochemistry. RESULTS: The expressions of CD97 and CD55 in rectal tumor tissues were significantly higher than those in normal colorectal tissues (P < 0.05, both). The patients with recurrence and/or metastasis had significantly higher expressions of CD97 at tumor cells and CD55 at stroma (67.8% [21/31] and 63.6% [21/33]) at the invasion front than those patients without recurrence and/or metastasis (25.0% [10/40] and 26.3% [10/38]). The expression of CD97 at tumor cell at the invasion front showed modest correlation with that of CD55 in the stroma at the invasion front(r = 0.392, P < 0.01). Univariate analysis revealed that lymph node metastasis (P = 0.001), stages II-IV (P = 0.026), and strong CD97 expression at tumor invasion front (P = 0.002) were shown to have a significant adverse impact on the postoperative survival rate. Moreover, lymph node metastasis (P = 0.037) and strong CD97 expression (P = 0.015) were associated with poor survival in a multivariate analysis. CONCLUSIONS: Elevated expression of CD97 and its ligand CD55 at the invasion front correlate with tumor recurrence and metastasis, and CD95 may be a poor prognostic factor for rectal adenocarcinoma.
Authors: G Aust; W Eichler; S Laue; I Lehmann; N E Heldin; O Lotz; W A Scherbaum; H Dralle; C Hoang-Vu Journal: Cancer Res Date: 1997-05-01 Impact factor: 12.701
Authors: C Hoang-Vu; K Bull; I Schwarz; G Krause; C Schmutzler; G Aust; J Köhrle; H Dralle Journal: J Clin Endocrinol Metab Date: 1999-03 Impact factor: 5.958
Authors: Joerg Galle; Doreen Sittig; Isabelle Hanisch; Manja Wobus; Elke Wandel; Markus Loeffler; Gabriela Aust Journal: Am J Pathol Date: 2006-11 Impact factor: 4.307
Authors: Zahra Madjd; Lindy G Durrant; Richard Bradley; Ian Spendlove; Ian O Ellis; Sarah E Pinder Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: Ian Spendlove; Judith M Ramage; Richard Bradley; Claire Harris; Lindy G Durrant Journal: Cancer Immunol Immunother Date: 2006-02-17 Impact factor: 6.968
Authors: Remond J A Fijneman; Rebecca A Anderson; Ethan Richards; Jieming Liu; Marianne Tijssen; Gerrit A Meijer; Janae Anderson; Annette Rod; Michael G O'Sullivan; Patricia M Scott; Robert T Cormier Journal: Cancer Sci Date: 2012-01-19 Impact factor: 6.716
Authors: Luca Badiali; Jonathan Cedernaes; Pawel K Olszewski; Olof Nylander; Anna V Vergoni; Helgi B Schiöth Journal: BMC Gastroenterol Date: 2012-09-25 Impact factor: 3.067